Middle East Respiratory Syndrome Coronavirus Accessory Protein 4a Is a Type I Interferon Antagonist

Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe acute respiratory infection with as yet unclear epidemiology. We previously showed that MERS-CoV counteracts parts of the innate immune response in human bronchiolar cells. Here we analyzed accessory proteins 3, 4a, 4b, and 5 for their abilities to inhibit the type I interferon response. Accessory protein 4a was found to block interferon induction at the level of melanoma differentiation-associated protein 5 (MDA5) activation presumably by direct interaction with double-stranded RNA.     

Mechanisms of Antiviral Action of Plant Antimicrobials against Murine Norovirus

Numerous plant compounds have antibacterial or antiviral properties; however, limited research has been conducted with nonenveloped viruses. The efficacies of allspice oil, lemongrass oil, and citral were evaluated against the nonenveloped murine norovirus (MNV), a human norovirus surrogate. The antiviral mechanisms of action were also examined using an RNase I protection assay, a host cell binding assay, and transmission electron microscopy. All three antimicrobials produced significant reductions (P ≤ 0.05) in viral infectivity within 6 h of exposure (0.90 log₁₀ to 1.88 log₁₀). After 24 h, the reductions were 2.74, 3.00, and 3.41 log₁₀ for lemongrass oil, citral, and allspice oil, respectively. The antiviral effect of allspice oil was both time and concentration dependent; the effects of lemongrass oil and citral were time dependent. Based on the RNase I assay, allspice oil appeared to act directly upon the viral capsid and RNA. The capsids enlarged from ≤35 nm to up to 75 nm following treatment. MNV adsorption to host cells was not significantly affected. Alternatively, the capsid remained intact following exposure to lemongrass oil and citral, which appeared to coat the capsid, causing nonspecific and nonproductive binding to host cells that did not lead to successful infection. Such contrasting effects between allspice oil and both lemongrass oil and citral suggest that though different plant compounds may yield similar reductions in virus infectivity, the mechanisms of inactivation may be highly varied and specific to the antimicrobial. This study demonstrates the antiviral properties of allspice oil, lemongrass oil, and citral against MNV and thus indicates their potential as natural food and surface sanitizers to control noroviruses.     

Pathogenesis of Chimeric MHV4/MHV-A59 Recombinant Viruses: the Murine Coronavirus Spike Protein Is a Major Determinant of Neurovirulence

The mouse hepatitis virus (MHV) spike glycoprotein, S, has been implicated as a major determinant of viral pathogenesis. In the absence of a full-length molecular clone, however, it has been difficult to address the role of individual viral genes in pathogenesis. By using targeted RNA recombination to introduce the S gene of MHV4, a highly neurovirulent strain, into the genome of MHV-A59, a mildly neurovirulent strain, we have been able to directly address the role of the S gene in neurovirulence. In cell culture, the recombinants containing the MHV4 S gene, S4R22 and S4R21, exhibited a small-plaque phenotype and replicated to low levels, similar to wild-type MHV4. Intracranial inoculation of C57BL/6 mice with S4R22 and S4R21 revealed a marked alteration in pathogenesis. Relative to wild-type control recombinant viruses (wtR13 and wtR9), containing the MHV-A59 S gene, the MHV4 S gene recombinants exhibited a dramatic increase in virulence and an increase in both viral antigen staining and inflammation in the central nervous system. There was not, however, an increase in the level of viral replication in the brain. These studies demonstrate that the MHV4 S gene alone is sufficient to confer a highly neurovirulent phenotype to a recombinant virus deriving the remainder of its genome from a mildly neurovirulent virus, MHV-A59. This definitively confirms previous findings, suggesting that the spike is a major determinant of pathogenesis.     

Origin and Possible Mode of Action of a Tissue Antagonist of Interferon

WE have presented data¹ supporting the hypothesis proposed by Taylor² and by Friedman and Sonnabend³ that interferon acts through a protein which confers the antiviral state on the cell. We postulated two separate regulatory mechanisms: one governing interferon synthesis and the other the production and action of the antiviral protein in the cell⁴. Our studies on the regulation of the antiviral state led us to the demonstration of a substance in human amniotic and chorionic membranes which, when added to the cell 4–18 h after interferon, decreased the antiviral state⁵. The extraction and purification of this tissue antagonist of interferon (TAI) have been previously described. TAI was resistant to proteases (trypsin, pepsin) and to nucleases (RNAase, DNAase). It was also resistant to heating at 56° C or 75° C for 1 h and was only inactivated at 95° C. Although the biologically active component was not chemically defined, its properties were reminiscent of mucopolysaccharides. It is unknown at present whether the TAI represents a substance or a group of substances.     

Identification of In Vivo-Interacting Domains of the Murine Coronavirus Nucleocapsid Protein

The coronavirus nucleocapsid protein (N), together with the large, positive-strand RNA viral genome, forms a helically symmetric nucleocapsid. This ribonucleoprotein structure becomes packaged into virions through association with the carboxy-terminal endodomain of the membrane protein (M), which is the principal constituent of the virion envelope. Previous work with the prototype coronavirus mouse hepatitis virus (MHV) has shown that a major determinant of the N-M interaction maps to the carboxy-terminal domain 3 of the N protein. To explore other domain interactions of the MHV N protein, we expressed a series of segments of the MHV N protein as fusions with green fluorescent protein (GFP) during the course of viral infection. We found that two of these GFP-N-domain fusion proteins were selectively packaged into virions as the result of tight binding to the N protein in the viral nucleocapsid, in a manner that did not involve association with either M protein or RNA. The nature of each type of binding was further explored through genetic analysis. Our results defined two strongly interacting regions of the N protein. One is the same domain 3 that is critical for M protein recognition during assembly. The other is domain N1b, which corresponds to the N-terminal domain that has been structurally characterized in detail for two other coronaviruses, infectious bronchitis virus and the severe acute respiratory syndrome coronavirus.The assembly of coronaviruses is driven principally by homotypic and heterotypic interactions between the two most abundant virion proteins, the membrane protein (M) and the nucleocapsid protein (N) (14, 32). The M protein is a triple-spanning transmembrane protein residing in the virion envelope, which is derived from the cellular budding site, the endoplasmic reticulum-Golgi intermediate compartment. More than half of the M molecule, its carboxy-terminal endodomain, is situated in the interior of the virion, where it contacts the nucleocapsid (46, 50). Also found in the virion envelope is the spike protein (S), which, although crucial for viral infectivity, is not an essential participant in assembly. The other canonical component of the coronavirus envelope is the small envelope protein (E), the function of which is enigmatic. Some evidence suggests that the E protein does not make sequence-specific contacts with other viral proteins (27) but instead functions by modifying the budding compartment, perhaps as an ion channel (56, 57). Alternatively, or additionally, E could act in a chaperone-like fashion to facilitate homotypic interactions between M protein monomers or oligomers (4).The N protein is the only protein constituent of the helically symmetric nucleocapsid, which is located in the interior of the virion. Coronavirus N proteins are largely basic phosphoproteins that share a moderate degree of homology across all three of the phylogenetic groups within the family (29). Some time ago, we proposed a model that pictured the N protein as comprising three domains separated by two spacers (A and B) (40). This arrangement was originally inferred from a sequence comparison of the N genes of multiple strains of the prototypical group 2 coronavirus, mouse hepatitis virus (MHV), and its validity seemed to be reinforced by numerous sequences that later became available. Part of this model, the delineation of spacer B and the acidic, carboxy-terminal domain 3, has been well supported by subsequent work (22, 25, 41, 42). However, a wealth of recent, detailed structural studies of bacterially expressed domains of the N proteins of the severe acute respiratory syndrome coronavirus (SARS-CoV) and of infectious bronchitis virus (IBV) has much more precisely mapped boundaries within the remainder of the N molecule (8, 16, 21, 23, 47, 51, 60). The latter studies have shown that the N protein contains two independently folding domains, designated the N-terminal domain (NTD) and the C-terminal domain (CTD). It should be pointed out that this nomenclature can be misleading: the NTD does not contain the amino terminus of the protein, and the CTD does not contain the carboxy terminus of the protein. Specifically, the CTD does not include spacer B and domain 3. The NTD and the CTD are separated by an intervening serine- and arginine-rich region; this region was previously noted to resemble the SR domains of splicing factors (42), and it has recently been shown to be intrinsically disordered (6, 7).In the assembled virion, the three known partners of the N protein are the M protein, the genomic RNA, and other copies of the N protein itself. We have sought to develop genetic and molecular biological methods that will begin to elucidate the varied ways in which the N molecule interacts during MHV infection. We previously found that the fusion of N protein domain 3 to a heterologous marker, green fluorescent protein (GFP), results in incorporation of GFP into virions (22). In the present study, we similarly fused each of the individual domains of N to GFP, and we thereby uncovered two strong modes of N protein-N protein interaction that likely contribute to virion architecture.     

Glucose-regulated Protein 78 Is an Intracellular Antiviral Factor against Hepatitis B Virus

Hepatitis B virus (HBV) infection is a global public health problem that plays a crucial role in the pathogenesis of chronic hepatitis, cirrhosis, and hepatocellular carcinoma. However, the pathogenesis of HBV infection and the mechanisms of host-virus interactions are still elusive. In this study, two-dimensional gel electrophoresis and mass spectrometry-based comparative proteomics were applied to analyze the host response to HBV using an inducible HBV-producing cell line, HepAD38. Twenty-three proteins were identified as differentially expressed with glucose-regulated protein 78 (GRP78) as one of the most significantly up-regulated proteins induced by HBV replication. This induction was further confirmed in both HepAD38 and HepG2 cells transfected with HBV-producing plasmids by real time RT-PCR and Western blotting as well as in HBV-infected human liver biopsies by immunohistochemistry. Knockdown of GRP78 expression by RNA interference resulted in a significant increase of both intracellular and extracellular HBV virions in the transient HBV-producing HepG2 cells concomitant with enhanced levels of hepatitis B surface antigen and e antigen in the culture medium. Conversely overexpression of GRP78 in HepG2 cells led to HBV suppression concomitant with induction of the positive regulatory circuit of GRP78 and interferon-β1 (IFN-β1). In this connection, the IFN-β1-mediated 2′,5′-oligoadenylate synthetase and RNase L signaling pathway was noted to be activated in GRP78-overexpressing HepG2 cells. Moreover GRP78 was significantly down-regulated in the livers of chronic hepatitis B patients after effective anti-HBV treatment (p = 0.019) as compared with their counterpart pretreatment liver biopsies. In conclusion, the present study demonstrates for the first time that GRP78 functions as an endogenous anti-HBV factor via the IFN-β1-2′,5′-oligoadenylate synthetase-RNase L pathway in hepatocytes. Induction of hepatic GRP78 may provide a novel therapeutic approach in treating HBV infection.Hepatitis B virus infection is a global public health problem. An estimated 2 billion (one-third of the world''s population) people are infected with HBV¹ worldwide, and more than 400 million are chronic hepatitis B (CHB) carriers (1). Epidemiological studies have shown that HBV infection is one of the major risk factors for chronic hepatitis, liver fibrosis, and hepatocellular carcinoma (HCC). Every year, over 1 million people die of HBV-related liver diseases, 30–50% of which are attributed to HCC (2). In China, more than 130 million (10% of the national population) people are suffering from CHB (3), and HCC has been ranked as the second major cause of cancer-related death since 1990 (4). However, the limited efficacy of antiviral therapies, high rates of post-treatment HBV relapse, and the emergence of drug-resistant viral mutants have greatly hindered the effective management of CHB infection. Therefore, it is of prime importance to understand the mechanisms of HBV-host interactions during malignant transformation in CHB infection to identify novel therapeutic anti-HBV targets.Because human HBV is incapable of infecting hepatocytes in vitro efficiently and the availability of reliable in vitro culture systems that favor HBV replication is limited, the pathogenetic studies of HBV and the development of anti-HBV drugs have long been hampered. HepAD38 and HepG2.2.15, both of which are derived from HepG2 cells and integrated with a greater than 1-unit-length HBV genome, have been widely accepted and are well established cell lines for the study of the HBV life cycle and screening potential HBV inhibitors since the late 1990s (5, 6). Recently comparative proteomics analysis of the HBV-expressing HepG2.2.15 cells and the parental HepG2 cells has been performed in two independent laboratories to characterize the altered proteome profile induced by HBV (7, 8). However, the different genetic backgrounds of HepG2.2.15 and HepG2 may lead to an inaccurate evaluation of the impact of HBV replication on host genes. When compared with HepG2.2.15 cells, which produce HBV particles in a continuous manner, HepAD38 cells produce higher levels of HBV DNA in a controllable and inducible way (5). HBV production in HepAD38 is under the strict control of a tetracycline-responsive promoter; therefore, a direct comparison of cellular characteristics with or without HBV replication in HepAD38 is easily achieved. To date, changes in the proteome profile of HepAD38 induced by HBV replication have not been reported. In this study, we performed comparative proteomics to globally analyze the host response to HBV by using an inducible HBV-producing cell line, HepAD38. The combination of two-dimensional gel electrophoresis (2-DE) and MALDI-TOF MS revealed that 23 cellular proteins were differentially expressed when HBV replicated. Among them, GRP78, which was one of the most highly up-regulated proteins, was further selected for functional assessment.     

胸腺五肽显著增强干扰素在抗病毒治程中的特异性CTL效应

目的:探究在e抗原(HBe Ag)阳性的慢性乙型肝炎患者采用聚乙二醇干扰素-2a(peg-2a)联合核苷类药物治疗过程中,加用胸腺五肽对细胞免疫应答的影响。方法:选择采用聚乙二醇干扰素α-2a联合核苷类药物(拉米夫定+阿德福韦酯)治疗48周,HBe Ag仍为阳性,且HLA-A2阳性的慢性乙型肝炎患者18例,分为两组。一组原方案延长联合治疗作为对照,另一组在原方案基础上再加用胸腺五肽治疗(10 mg/次,2次/周,共24周)治疗,所有病人均治疗至96周。并做体外HBV特异性细胞毒T淋巴细胞(HBV specific CTL)培养增殖,通过Elispot技术分析其分泌细胞因子(肿瘤坏死因子-α,干扰素-γ,白介素-10)的功能。结果:HBe Ag转阴率,治疗96周时联合胸腺五肽组为44.4%(4/9),原方案对照组为22.2%(2/9)。HBs Ag滴度,48周时,HBs Ag为4571±3772 IU/m:;96周时,联合胸腺五肽组为1962±2869 IU/m L,转阴1人,原方案对照组为3490±3124 IU/m L,P=0.093。HBV特异性CTL培养增殖,96周时联合胸腺五肽组高于原方案对照组,且联合胸腺五肽组TNF-的分泌也高于原方案对照组,P0.05。结论:胸腺五肽显著增强干扰素抗病毒治疗过程中的特异性CTL效应。